Valuation: Ocular Therapeutix, Inc.

Market Cap 1.86B 1.64B 1.52B 1.4B 2.63B 179B 2.66B 18.11B 7.07B 88.18B 6.99B 6.84B 305B P/E 2026 *
-5.4x
P/E 2027 * -6.13x
Enterprise Value 1.5B 1.32B 1.23B 1.13B 2.12B 144B 2.14B 14.58B 5.7B 70.99B 5.63B 5.51B 245B EV / Sales 2026 *
28.9x
EV / Sales 2027 * 15.3x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day+1.59%
1 week-3.68%
Current month-12.02%
1 month-12.20%
3 months-8.96%
6 months-20.66%
Current year-28.83%
1 week 8.32
Extreme 8.32
9.14
1 month 8.32
Extreme 8.32
10.94
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Don

Chief Executive Officer

-100,184 0.0473%
10/06/26 Free

Director

58,000 0.0274%
10/06/26 Free

Director

58,000 0.0274%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%-3.68%-29.24%+96.36% 1.86B
+0.13%+1.56%+47.35%+164.01% 1,067B
+0.97%+5.10%+58.02%+53.98% 635B
-0.94%+0.95%+35.02%+81.05% 458B
+1.41%+7.75%+38.93%+32.88% 347B
+1.28%+2.82%+38.42%+43.21% 295B
+1.72%+2.33%+19.31%+20.79% 262B
+1.84%-1.03%-27.78%-38.45% 216B
+0.06%+2.72%+22.73%+59.97% 203B
+0.94%-2.80%+12.32%+69.09% 161B
Average +1.22%+0.68%+21.51%+58.29% 364.54B
Weighted average by Cap. +0.92%+1.95%+36.71%+79.85%

Financials

2026 *2027 *
Net sales 51.91M 45.63M 42.48M 39.01M 73.25M 4.98B 74.22M 505M 197M 2.46B 195M 191M 8.5B 120M 106M 98.48M 90.45M 170M 11.54B 172M 1.17B 457M 5.7B 452M 442M 19.7B
Net income -362M -318M -296M -272M -510M -34.69B -517M -3.52B -1.37B -17.13B -1.36B -1.33B -59.21B -331M -291M -271M -248M -467M -31.7B -473M -3.22B -1.26B -15.65B -1.24B -1.21B -54.11B
Net Debt -363M -319M -297M -273M -512M -34.81B -519M -3.53B -1.38B -17.19B -1.36B -1.33B -59.41B -18M -15.82M -14.73M -13.53M -25.4M -1.73B -25.74M -175M -68.38M -852M -67.57M -66.11M -2.95B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
28/07/26 $8.640 +1.59% 1,539,828
24/07/26 $8.505 -1.33% 1,166,170
23/07/26 $8.620 +0.41% 1,811,982
22/07/26 $8.585 -3.86% 1,865,677
21/07/26 $8.930 +2.53% 1,584,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.640USD
Average target price
27.09USD
Spread / Average Target
+213.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock